Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis
Andrology · 2026-09 · 14 (6) · 1627-1635
DOI: 10.1111/andr.70222 ↗At a glance
Journal article in Andrology, published online on 2026-03-26. Written by Shan Lin and 3 co-authors. Institution: Department of Respiratory and Critical Care Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China. Major MEDLINE topics: Erectile Dysfunction, Hypoglycemic Agents. Cited 2 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Research Development Plan Project of Affiliated Hospital of North Sichuan Medical College, Science and Technology Project of Nanchong, Sichuan Province Clinical Key Specialty Construction Project.
Abstract (original language)
Background
Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains underrecognized. The objective of this study was to investigate whether commonly prescribed antidiabetic medications, including glucagon‐like peptide‐1 receptor agonists, dipeptidyl peptidase‐4 inhibitors, metformin, and sodium‐glucose cotransporter‐2 inhibitors, are associated with an increased reporting of erectile dysfunction in real‐world clinical practice.
Methods
This retrospective pharmacovigilance study was conducted using the FDA Adverse Event Reporting System. A disproportionality analysis was performed to evaluate the reporting frequency of erectile dysfunction associated with commonly prescribed antidiabetic medications. The reporting odds ratio served as the primary metric for evaluating disproportionality in adverse event reporting. In addition, time‐to‐onset and Weibull shape parameter analyses were performed to assess temporal trends in adverse event occurrence.
Results
We identified 49 semaglutide‐, 54 sitagliptin‐, and 42 dapagliflozin‐associated erectile dysfunction reports. All three drugs demonstrated significant disproportionality signals: semaglutide (reporting odds ratio: 1.53, 95% confidence interval: 1.16–2.03; information component 025 = 0.19), sitagliptin (reporting odds ratio: 1.52, 95% confidence interval: 1.16–1.98; information component 025 = 0.20), and dapagliflozin (reporting odds ratio: 1.51, 95% confidence interval: 1.11–2.04; information component 025 = 0.13). Time‐to‐onset analysis indicated a random failure‐type distribution for all three drugs (semaglutide, sitagliptin, and dapagliflozin), suggesting that the occurrence of erectile dysfunction appears relatively random over the course of treatment rather than concentrated shortly after initiation and underscoring the need for continuous monitoring throughout therapy. Other agents in the same drug classes, including dulaglutide, linagliptin, and metformin, did not show significant signals.
Conclusions
This FDA Adverse Event Reporting System‐based pharmacovigilance analysis identified potential safety signals linking erectile dysfunction to semaglutide, sitagliptin, and dapagliflozin. These findings do not establish causality and should be regarded as preliminary and hypothesis‐generating. Further mechanistic and prospective clinical studies are needed to determine whether these signals reflect true drug‐related risks. Clinicians should be aware that erectile dysfunction has been reported in some users of these agents and may consider incorporating sexual health into routine discussions and shared decision‐making with male patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Respiratory and Critical Care Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
- Department of Critical Care Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
- Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
ORCID profiles: Shan Lin, Qingyuan Zhan
Funding
- Research Development Plan Project of Affiliated Hospital of North Sichuan Medical College
- Science and Technology Project of Nanchong
- Sichuan Province Clinical Key Specialty Construction Project
- Scientific Research and Development Program Project
- Project of the Doctoral Initiation Fund
- Key Project of the Affiliated Hospital of North Sichuan Medical College
Cite
APA
Lin, S., Ding, X., Dang, X., & Zhan, Q. (2026). Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis. Andrology, 14(6), 1627-1635. https://doi.org/10.1111/andr.70222
Vancouver
Lin S, Ding X, Dang X, Zhan Q. Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis. Andrology. 2026;14(6):1627-1635. doi:10.1111/andr.70222
BibTeX
@article{Lin2026,
author = {Lin, Shan and Ding, Xuefeng and Dang, Xin and Zhan, Qingyuan},
title = {Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis},
journal = {Andrology},
year = {2026},
volume = {14},
number = {6},
pages = {1627--1635},
doi = {10.1111/andr.70222}
}
EUVIMED